GRAIL (GRAL) closed at $122.42 on Oct 19, 2026, up 3.9% on the day. The stock is up 51.6% over the past month, up 68.4% over three months, up 43.0% year to date and up 41.7% over the past year. It trades 26.5% below its 52-week high of $166.48 and 195.0% above its 52-week low of $41.50. The close sits above its 50-day moving average ($99.60) and above its 200-day moving average ($76.23).
NextPick tracks GRAL in its Liquid Biopsy basket alongside NTRA, GH and PSNL. As of Oct 19, 2026, the basket's money-flow score is -20 (weak outflow), and the basket is down 3.2% over five sessions. Over the past month GRAL ranks 1st of 4 basket members by price change.
Yes — the Oct 19, 2026 close of $122.42 is 60.6% above the 200-day average of $76.23.
GRAL closed 26.5% below its 52-week high of $166.48.
NextPick groups GRAL with NTRA, GH and PSNL in its Liquid Biopsy basket.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
